Leukemia section

Leukemia News and Features

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

Relapsed Ph-Negative Acute Lymphoblastic Leukemia Incurs a High Economic Burden

Recent study findings investigated the economic burden of patients with relapsed Ph-negative ALL, and the adverse events of special interest that are most likely to have the greatest impact. These findings were presented at ASH 2017.

More Communication, Support Needed to Manage Symptom Burden in CML

More Communication, Support Needed to Manage Symptom Burden in CML

Despite advancements in treatment of CML, many patients still experience adverse effects of their disease and treatments. Therefore, researchers conducted a survey of patients to determine whether they felt assistance and support met their needs.

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers

What is the concern behind PARP inhibitors and leukemia?

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Reduced Delayed Intensification Impacts Risk of Pediatric ALL Relapse

Improved survival in pediatric patients with standard-risk ALL has shifted the focus toward reducing treatment burden and toxicity; therefore, researchers sought to determine the effects of reduced DI chemotherapy on relapse and survival.

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

Dasatinib Granted Regular FDA Approval for Ph+ CML in Pediatric Patients

US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs